Role of the androgen signaling axis in genitourinary malignancies

Shinder, Brian; Shupe, Adam; Lee, Geun Taek; Stein, Mark N.; Kim, Isaac Y.; Singer, Eric A.

doi:10.21037/tcr.2018.03.41

Cited by 3 publications

(4 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We identified 42,406 patients with BPH, of whom 27.7% were Black, 27.7% were White and 14.8% were Hispanic. Overall, finasteride was prescribed in 13.4% of patients (5,698). The prevalence of finasteride use increased from 7.2% in 2000 to 16.9% in 2007; however, between 2008 and 2016 the prevalence ranged from 12% to 14%.…”

Section: Resultsmentioning

confidence: 99%

“…4 Several animal and clinical studies have demonstrated a positive association between androgen receptor signaling with the development of BCa. 5,6 Five a-reductase inhibitors inhibit the production of dihydrotestosterone and downregulate AR-dependent pathways. 7,8 Clinical studies have demonstrated that androgen suppression therapy using 5ARI, or androgen deprivation therapy using androgen receptor antagonists/continuous GnRH, can reduce BCa incidence or decrease BCa recurrence after transurethral resection.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Finasteride Use and Risk of Bladder Cancer in a Multiethnic Population

et al. 2021

View full text Add to dashboard Cite

Purpose: Finasteride use has been associated with a reduced incidence of bladder cancer. However, the majority of studies have been conducted primarily in East Asian or White populations. Given differences in the incidence of bladder cancer among racial/ethnic groups, it is important to determine whether the effect of finasteride use on bladder cancer varies by race/ethnicity. Materials and Methods: We identified all patients with a diagnosis of benign prostatic hyperplasia between 2000 and 2016 at our academic health center in Bronx, New York via an electronic medical record database. We then identified patients who were prescribed finasteride, and those who developed bladder cancer during followup. We used competing risk analysis to examine associations of finasteride use with risk of bladder cancer, adjusting for age, smoking and race/ethnicity. Results: We identified 42,406 patients with benign prostatic hyperplasia (aver-ageAESD age 67AE12.9 years), of whom 27.7% were Black and 14.8% were Hispanic. Finasteride was prescribed in 5,698 patients (13.4%). Bladder cancer was diagnosed in 84 of 5,698 finasteride users (1.5%), compared to 762 of 36,708 nonusers (2.1%, log-rank p[0.003). Finasteride was associated with a 36% reduction in risk of bladder cancer (HR: 0.64, 95% CI: 0.51e0.80; p <0.0001) among all patients. When data were stratified by race/ethnicity, finasteride use was associated with a reduction in risk of bladder cancer in White men (HR: 0.61, 95% CI: 0.43e0.86; p[0.005) and Hispanic men (HR: 0.44, 95% CI: 0.21e0.90; p[0.026), but there was no association among Black men (HR: 1.01, 95% CI: 0.67e1.51; p[0.964). Conclusions: Our study corroborates previous findings that men who are on finasteride have a lower bladder cancer incidence. However, the reduction in risk was seen only in White and Hispanic men, but not among Black men. Therefore, race/ethnicity represents an important stratification factor for future larger studies on finasteride as chemoprevention for bladder cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

Finasteride Use and Risk of Bladder Cancer in a Multiethnic Population

et al. 2021

View full text Add to dashboard Cite

show abstract

“…For example, androgen signaling is one of the important pathways in PC. Many studies found the role of androgen receptors in RC, and there are multiple ongoing clinical trials that examine therapeutic agents targeting androgen receptor in RC [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

Urinary microbiome profile in men with genitourinary malignancies

et al. 2022

View full text Add to dashboard Cite

Purpose Recent advances in molecular biology technology have allowed identification of microbial communities in the urinary tract, and urinary microbiome is associated with various urological diseases. In this study, we aimed to characterize the urinary microbiome of genitourinary malignancies. Materials and Methods Metagenomic analysis of urinary DNA was performed in 85 patients including 30 with bladder cancer (BC), 27 with prostate cancer (PC), 12 with renal cancer (RC), and 16 with non-cancer (NC). 16S rRNA gene sequencing was conducted after amplification of the V3–V4 region. Results PC and RC had significantly lower Shannon index than BC, and beta diversity showed significantly different microbiome composition between four groups. We identified six genera of Cutibacterium , Peptoniphilus , Sphingomonas , Staphylococcus , Micrococcus , and Moraxella , which showed significantly different abundance between the four groups. When each of the malignancies were compared to NC at the species level, Micrococcus sp. was significantly increased in BC. We also identified 12 and five species with increased populations in PC and RC, respectively. Of these, Cutibacterium acnes , Cutibacterium granulosum , Peptoniphilus lacydonensis , and Tessaracoccus were significantly increased in both PC and RC. Conclusions Urinary microbiome composition was different depending on the xlink:type of genitourinary malignancies, and we identified bacteria that are significantly associated with each xlink:type of malignancy. Specifically, several bacterial species were associated both PC and RC, suggesting that PC and RC share a similar pathogenesis-related urinary microbiome.

show abstract

“…In an orthotopic kidney capsule model, miR-145 suppresses tumor growth and metastasis of OS-RC2 cells (117). ccRCC patients with higher AR expression had lower overall survival rates, linking AR to poor prognosis (118). AR in ccRCC cells increases proliferation and AR inhibitors enzalutamide and abiraterone inhibit TG of Caki-1 xenografts in nude mice (119).…”

Section: Mir-205-5p (Vegf) Expression Of Mir-205-5p (Figurementioning

confidence: 99%

Clear Cell Renal Carcinoma: MicroRNAs With Efficacy in PreclinicalIn VivoModels

Weidle

Nopora

2021

Cancer Genomics Proteomics

View full text Add to dashboard Cite

In order to identify new targets and treatment modalities for clear cell renal carcinoma, we surveyed the literature with respect to microRNAs involved in this disease. In this review, we have focused on up-and down-regulated miRs which mediate efficacy in preclinical clear-cell renal carcinoma-related in vivo models. We have identified 10 upregulated and 33 down-regulated micro-RNAs according to this criterion. As proof-of-concept, micro-RNAs interfering with VEGF (miR-205p) and mTOR (mir-99a) pathways, which are modulated by approved drugs for this disease, have been identified. miRs targeting hypoxia induced factor-2α (HIF-2α) (miR-145), E3 ubiquitinylases speckle-type POZ protein (SPOP) (miR 520/372/373) and casitas B-lineage lymphoma (CBL) (miR-200a-3p), interfere with druggable targets. Further identified miRs interfere with cell-cycle dependent kinases, such as CDK2 CDK4, 9 (206c). Transmembrane receptor Ral interacting protein of 76 kD (RLIP76), targeted by mir-137, has emerged as another important target for ccRCC. Additional miRs and their targets merrying further preclinical validation are discussed.

show abstract

Role of the androgen signaling axis in genitourinary malignancies

Cited by 3 publications

References 40 publications

Finasteride Use and Risk of Bladder Cancer in a Multiethnic Population

Finasteride Use and Risk of Bladder Cancer in a Multiethnic Population

Urinary microbiome profile in men with genitourinary malignancies

Clear Cell Renal Carcinoma: MicroRNAs With Efficacy in PreclinicalIn VivoModels

Contact Info

Product

Resources

About